Literature DB >> 2856924

Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.

D N Carney, G S Ahluwalia, H N Jayaram, D A Cooney, D G Johns.   

Abstract

The antitumor activity of the antineoplastic agent, tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide), has previously been shown to require intracellular anabolism of the drug to a nicotinamide adenine dinucleotide (NAD) analog (2-beta-D-ribofuranosylthiazole-4-carboxamide adenine dinucleotide or "tiazofurin adenine dinucleotide"), which then acts as a potent inhibitor of the target enzyme inosine monophosphate (IMP) dehydrogenase. Inhibition of the latter enzyme in turn brings about a profound depletion of intracellular guanosine nucleotides essential for tumor cell growth and replication. In the present study, the cytotoxicity and metabolism of tiazofurin have been examined in six human lung cancer cell lines. At the pharmacologically attainable drug concentration of 100 microM, colony survival was less than 1.5% in three cell lines ("sensitive"), while survival in the remaining three was greater than 50% ("resistant"). The metabolism of tritiated tiazofurin was examined at concentrations ranging from 0.5 to 100 microM following both brief (6 h) and protracted (14 d) exposures. The sensitive lines accumulated concentrations of tiazofurin adenine dinucleotide that were approximately 10 times those achieved by the resistant lines at both time points. We also observed tendencies for the sensitive cell lines to exhibit: (a) higher specific activities of NAD pyrophosphorylase, the enzyme required for the synthesis of tiazofurin adenine dinucleotide, (b) significantly lower levels of a phosphodiesterase which degrades the latter dinucleotide, (c) greater inhibition of the target enzyme IMP dehydrogenase, and (d) greater depressions of guanosine nucleotide pools after drug treatment. By contrast, the basal levels of IMP dehydrogenase and purine nucleotides in these six lines did not correlate in any obvious way with their responsiveness or resistance. The accumulation and monophosphorylation of parent drug were also not prognostic variables. These studies thus suggest that the extent of accumulation of tiazofurin adenine dinucleotide, as regulated by its synthetic and degradative enzyme activities, is the single most predictive determinant of the responsiveness of cultured human lung tumor cells to tiazofurin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2856924      PMCID: PMC423424          DOI: 10.1172/JCI111671

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides.

Authors:  J T Witkowski; R K Robins; R W Sidwell; L N Simon
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

2.  Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.

Authors:  A F Gazdar; D N Carney; E K Russell; H L Sims; S B Baylin; P A Bunn; J G Guccion; J D Minna
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

3.  An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchangers.

Authors:  J X Khym
Journal:  Clin Chem       Date:  1975-08       Impact factor: 8.327

4.  Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.

Authors:  R F Ozols; J K Willson; M D Weltz; K R Grotzinger; C E Myers; R C Young
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

5.  Response of cultured human brain tumors to nitrosoureas: correlation with clinical data.

Authors:  P L Kornblith; B H Smith; L A Leonard
Journal:  Cancer       Date:  1981-01-15       Impact factor: 6.860

6.  In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma.

Authors:  M M Siegel; H S Chung; N Rucker; S E Siegel; R C Seeger; H Isaacs; W F Benedict
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

7.  Positive correlation between histological tumor involvement and generation of tumor cell colonies in agarose in specimens taken directly from patients with small-cell carcinoma of the lung.

Authors:  D N Carney; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  1980-06       Impact factor: 12.701

8.  Activity of mitoxantrone in a human tumor cloning system.

Authors:  D D Von Hoff; C A Coltman; B Forseth
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

9.  The poor cloning ability in agar of human tumour cells from biopsies of primary tumours.

Authors:  H T Rupniak; B T Hill
Journal:  Cell Biol Int Rep       Date:  1980-05

10.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

View more
  6 in total

1.  Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors:  T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  Clinical toxicity associated with tiazofurin.

Authors:  J L Grem; L Rubinstein; S A King; B D Cheson; M J Hawkins; D D Shoemaker
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.

Authors:  K Pillwein; H N Jayaram; G Weber
Journal:  Blut       Date:  1988-08

4.  Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.

Authors:  H N Jayaram; K Murayama; K Pillwein; W Zhen; G Weber
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  R M Green; D J Stewart; J A Maroun
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Growth inhibition and induction of phenotypic alterations in MCF-7 breast cancer cells by an IMP dehydrogenase inhibitor.

Authors:  Y Sidi; C Panet; L Wasserman; A Cyjon; A Novogrodsky; J Nordenberg
Journal:  Br J Cancer       Date:  1988-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.